Vapotherm Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results
Vapotherm (NYSE: VAPO) announced preliminary unaudited revenue results for Q4 and full year 2020. Q4 revenue is projected at $40.6 million, a 212% increase from $13.0 million in Q4 2019. For the full year, expected revenue is $125.4 million, a 161% rise compared to $48.1 million in 2019. The growth is attributed to increased demand during the COVID-19 pandemic and expanded production capabilities. Vapotherm’s installed base of Precision Flow systems significantly increased, with better disposable utilization rates. Full financial results will be released in late February 2021.
- Q4 2020 revenue expected at $40.6 million, up 212% YoY.
- Full year 2020 revenue expected at $125.4 million, up 161% YoY.
- Increased demand for products due to COVID-19.
- None.
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced certain preliminary unaudited fourth quarter and full year 2020 revenue results.
Preliminary revenue for the fourth quarter of 2020 is expected to be approximately
Preliminary revenue for the full year 2020 is expected to be approximately
“2020 was a transformational year for Vapotherm. Due to COVID-19, we saw customer demand increase significantly in both new and existing accounts, resulting in increased awareness of our high velocity therapy for treating patients with respiratory distress. In response, we successfully expanded our production capabilities, and we continue to treat fulfillment of customer orders as our highest priority. As a result, our worldwide installed base of Precision Flow systems expanded significantly and disposable utilization rates are better than prior years.” said Joe Army, President and CEO of Vapotherm. “As we move into 2021, we expect to continue to add to our portfolio of high clinical value products and expand our body of clinical evidence, with the goal of driving further adoption of our Hi-VNI Technology products.”
The Company plans to release its fourth quarter and full year 2020 financial results in late February 2021. The quarterly and annual revenue estimates for 2020 included in this press release are preliminary. Actual fourth quarter and full year 2020 revenue results are subject to the completion of the Company’s year-end financial closing procedures and review and audit procedures by the Company’s independent registered public accounting firm.
About Vapotherm
Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 2.5 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com.
Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The Precision Flow system’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.
Website Information
Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm’s disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm’s website, in addition to following Vapotherm’s press releases, Securities and Exchange Commission (“SEC”) filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm’s website is not incorporated by reference into, and is not a part of, this document.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements, including statements about expected revenue for the fourth quarter and fiscal year 2020, expansion of Vapotherm’s product portfolio and body of clinical evidence, and anticipated adoption of Vapotherm products. In some cases, you can identify forward-looking statements by terms such as ‘‘expect,’’ “guide” or “typically” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to the following: Vapotherm has incurred losses in the past and may be unable to achieve or sustain profitability in the future, Vapotherm may need to raise additional capital to fund its existing commercial operations, develop and commercialize new products, and expand its operations, Vapotherm’s dependence on sales generated from its Precision Flow systems, competition from multi-national corporations who have significantly greater resources than Vapotherm and are more established in the respiratory market, the ability for Precision Flow systems to gain increased market acceptance, its inexperience directly marketing and selling its products, the potential loss of one or more suppliers, Vapotherm’s susceptibility to seasonal fluctuations, Vapotherm’s failure to comply with applicable United States and foreign regulatory requirements, the failure to obtain U.S. Food and Drug Administration or other regulatory authorization to market and sell future products or its inability to secure, maintain, or enforce patent or other intellectual property protection for its products, the impact of the COVID-19 pandemic on its business, including its supply chain, and the other risks and uncertainties included under the heading “Risk Factors” in Vapotherm’s Annual Report on Form 10-K for the fiscal year ended December, 31, 2019, as filed with the SEC on March 4, 2020, Vapotherm’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as filed with the SEC on May 5, 2020, Vapotherm’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, as filed with the SEC on August 4, 2020, Vapotherm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as filed with the SEC on November 4, 2020, and Vapotherm’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2021 and in any subsequent filings with the SEC. The forward-looking statements contained in this press release reflect Vapotherm’s views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005216/en/
FAQ
What is Vapotherm's revenue forecast for Q4 2020?
How did Vapotherm perform in the full year 2020?
When will Vapotherm release its full financial results for 2020?
What factors contributed to Vapotherm's revenue growth in 2020?
